Galenica's Revenue Growth Despite a Demanding Market

During the first four months of 2026, Galenica AG posted significant revenue growth, reaching CHF 1,409.7 million, an increase of 7.3%. This growth was primarily driven by strong performance in the pharmacy and wholesale sectors.

The Home Care and Diagnostics sectors also made a positive contribution. Although the market experienced a seasonal decline in cold and flu medications, Galenica's diversification helped mitigate the negative impacts.

The Products & Care segment saw its revenue grow by 11.6%, driven by increased demand for weight-loss preparations. Although the Logistics & IT segment showed growth of 4.3%, Galenica expects to maintain its momentum with a projected increase in EBIT1 of between 6% and 8% for 2026.